Clinical Laserthermia Systems AB Class B

As of June 30, 2026, Clinical Laserthermia Systems AB Class B carries a market capitalization of 107.21M, placing it among publicly traded companies globally. Its enterprise value stands at 100.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Clinical Laserthermia Systems AB Class B's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Clinical Laserthermia Systems AB Class B has 31.49M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 8.14, and the price-to-book ratio stands at 2.24.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 100.00M versus a market cap of 107.21M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Clinical Laserthermia Systems AB Class B maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Clinical Laserthermia Systems AB Class B posted a negative return on equity (ROE) of -68.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -56.97, reflecting losses generated across the asset base. The company generates approximately 965,846.15 in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.87 indicates how many times Clinical Laserthermia Systems AB Class B sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Clinical Laserthermia Systems AB Class B's stock has declined approximately 75.92% over the past 52 weeks. The 50-day moving average sits at 1.83, while the 200-day moving average is 3.95.

Over the twelve months ended June 30, 2026, Clinical Laserthermia Systems AB Class B generated 12.56M in revenue and converted that into -39.49M in net income, yielding earnings per share of -1.33. EBITDA reached -38.56M, while operating income came in at -41.21M.

These figures are as of June 30, 2026. Total book value stands at 47.84M, with working capital of -1.59M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Clinical Laserthermia Systems AB Class B posted a gross margin of 55.56, reflecting its pricing power and cost economics. The operating margin of -328.20 and net profit margin of -314.55 provide insight into operational efficiency.

Clinical Laserthermia Systems AB Class B's most recent stock split took place on July 30, 2026.

As of June 30, 2026, Clinical Laserthermia Systems AB Class B has an Altman Z-Score of 0.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.